Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients

Markus Priller, Julia Pöschl, Leticia Abrão, AndréO Von Bueren, Yoon-Jae Cho, Stefan Rutkowski, Hans A. Kretzschmar, Ulrich Schüller

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Purpose: The transcription factor Forkhead boxM1(FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P=0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1may be used as an additional prognosticmarker andmay represent a potential novel target to treat patients suffering from medulloblastoma.

Original languageEnglish (US)
Pages (from-to)6791-6801
Number of pages11
JournalClinical Cancer Research
Volume17
Issue number21
DOIs
StatePublished - Nov 1 2011
Externally publishedYes

Fingerprint

Medulloblastoma
Cell Proliferation
Survival
Growth
Forkhead Transcription Factors
Neurons
Thiazoles
Cell Line
Spindle Apparatus
Caspases
Brain Neoplasms
Neoplasms
Cell Survival
Cell Cycle
Research Design
Down-Regulation
Multivariate Analysis
Immunohistochemistry
Anti-Bacterial Agents
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. / Priller, Markus; Pöschl, Julia; Abrão, Leticia; Von Bueren, AndréO; Cho, Yoon-Jae; Rutkowski, Stefan; Kretzschmar, Hans A.; Schüller, Ulrich.

In: Clinical Cancer Research, Vol. 17, No. 21, 01.11.2011, p. 6791-6801.

Research output: Contribution to journalArticle

Priller, M, Pöschl, J, Abrão, L, Von Bueren, A, Cho, Y-J, Rutkowski, S, Kretzschmar, HA & Schüller, U 2011, 'Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients', Clinical Cancer Research, vol. 17, no. 21, pp. 6791-6801. https://doi.org/10.1158/1078-0432.CCR-11-1214
Priller, Markus ; Pöschl, Julia ; Abrão, Leticia ; Von Bueren, AndréO ; Cho, Yoon-Jae ; Rutkowski, Stefan ; Kretzschmar, Hans A. ; Schüller, Ulrich. / Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 21. pp. 6791-6801.
@article{dc8edd1bcd934d4a93228b7bafd8fc4b,
title = "Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients",
abstract = "Purpose: The transcription factor Forkhead boxM1(FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P=0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1may be used as an additional prognosticmarker andmay represent a potential novel target to treat patients suffering from medulloblastoma.",
author = "Markus Priller and Julia P{\"o}schl and Leticia Abr{\~a}o and {Von Bueren}, Andr{\'e}O and Yoon-Jae Cho and Stefan Rutkowski and Kretzschmar, {Hans A.} and Ulrich Sch{\"u}ller",
year = "2011",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-11-1214",
language = "English (US)",
volume = "17",
pages = "6791--6801",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients

AU - Priller, Markus

AU - Pöschl, Julia

AU - Abrão, Leticia

AU - Von Bueren, AndréO

AU - Cho, Yoon-Jae

AU - Rutkowski, Stefan

AU - Kretzschmar, Hans A.

AU - Schüller, Ulrich

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Purpose: The transcription factor Forkhead boxM1(FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P=0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1may be used as an additional prognosticmarker andmay represent a potential novel target to treat patients suffering from medulloblastoma.

AB - Purpose: The transcription factor Forkhead boxM1(FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P=0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1may be used as an additional prognosticmarker andmay represent a potential novel target to treat patients suffering from medulloblastoma.

UR - http://www.scopus.com/inward/record.url?scp=80455162327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80455162327&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-1214

DO - 10.1158/1078-0432.CCR-11-1214

M3 - Article

C2 - 21918172

AN - SCOPUS:80455162327

VL - 17

SP - 6791

EP - 6801

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -